Medidata and InventisBio Extend Collaboration with Enterprise-Wide Decentralized Clinical Trials
SHANGHAI, China, September 27, 2022 - Medidata, a Dassault Systèmes company and a leading global provider of cloud-based solutions for life sciences clinical research, and InventisBio recently announced a strategic partnership that extends the scope of their collaboration to the enterprise level. Medidata's leading unified platform in clinical trials will be more widely and flexibly applied to InventisBio's global and local projects, further enabling efficient trial operation and exploring more possibilities for decentralized clinical trials (DCTs).
The partnership between Medidata and InventisBio began in 2017, and Medidata Rave EDC (Electronic Data Capture) and RTSM (Randomization and Trial Supply Management) have helped InventisBio flexibly respond to clinical studies of different phases and sizes, accelerating trial start-up and enabling efficient operations. In the face of the COVID-19 pandemic from 2020 to present and with an aim to tackle the difficulties of patients not being able to go to study hospitals to complete visits, InventisBio employed Rave RTSM in conjunction with offline logistics management to fulfill the pickup and dispatch of drugs from study hospitals and central depots to patients. The application of investigational drug delivery directly to patients greatly enhances the convenience of clinical trial participation for patients and availability of investigations product.
Mr. Shi Yongyong, Senior Director of Clinical Operations of InventisBio, said, "Driven by AI, other innovative technologies, as well as regulatory changes, we recognize that patient-centric decentralized trials are the future development direction of clinical trials. The deployment of direct drug delivery to patients (DtP) model during the pandemic will be our first step to explore the feasibility of DCTs on our own. Of course, we must still recognize the power of Rave EDC as a solid foundation for patient-centric discovery, such as the ability to transfer patients from a study hospital in an epidemic area to another study hospital without having to change subject numbers or worry about the risk of unblinding or bias. This flexibility is why we have come to trust Medidata's unified platform."
Rave RTSM has unsurpassed DtP capabilities giving sponsors and CROs the highest level of flexibility for decentralized and hybrid clinical trials. DCTs can be enabled for any combination of sites and visits and provides sites the ability to determine the sources of drug dispensation with the least burden for their patients.
Commenting on the enterprise-level collaboration signed between the two companies, Mr. Shi Yongyong said, "InventisBio values the role of innovation in corporate growth and is very willing to leverage innovative technologies to fuel breakthroughs in our research and development. We are delighted to further deepen our collaboration with our old friend Medidata. Thanks to Medidata's flexible partnership model, we are able to tailor our partnership to meet our own development needs. We look forward to an enterprise-level partnership framework in which InventisBio can empower the development of innovative drugs with superior data insights and more efficient trials for the ultimate benefit of patients."
"We are honored to enter into this enterprise-level partnership with our long-time friend, InventisBio," said Ms. Wei Li, General Manager, Medidata China, Dassault Systèmes. “With more than 20 years of experience in clinical trials, Medidata has worked with many customers in China and abroad to deliver superior insights with high-quality data sets to empower the R&D process. With its flexible, project-based collaboration model and exceptional sales team, Medidata is able to work with biotech companies like InventisBio to customize collaboration models that ensure our work together to solve the impossible. In the future, we look forward to helping more biotech companies in China with their research and development processes, driving even better results and benefiting more patients."
Medidata is a wholly-owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 2,000+ customers and partners access the world's most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata
About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production to achieve a more sustainable world for patients, citizens, and consumers. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com
3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.